Alerta

ALECTINIB FOR THE TREATMENT OF ALK FUSION-POSITIVE SOLID OR CNS TUMOURS

Resumen de: AU2024380949A1

The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.

ANTI-BCMA SINGLE-DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: AU2024358317A1

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY IN CTDNA HIGH RISK PATIENTS

Resumen de: AU2024366453A1

The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.

USE OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) IN RARE ANEMIA

Resumen de: AU2024369003A1

The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).

METHODS, REAGENTS AND KITS FOR DETECTING MINIMAL/MEASURABLE DISEASE IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL)

Resumen de: AU2024352563A1

The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.

BISPECIFIC ANTIBODIES THAT BIND CD3 AND THE GANGLIOSIDE NGCGM3

Resumen de: AU2024338945A1

The present invention relates to the field of biotechnology and immuno-oncology. The present invention discloses bispecific antibodies comprising an antibody, antibody fragment or single chain variable fragment that recognise the ganglioside NGcGM3 in tumour cells and an antibody, antibody fragment or single chain variable fragment that recognise the antigen CD3 in human immune effector cells. These bispecific antibodies are characterised by their ability to mediate selective cytotoxicity in NGcGM3-positive tumour cells, and not in normal cells which may express the ganglioside and allow the recruitment of not only T lymphocytes, but also NKT cells. The bispecific antibodies of the present invention and the nucleic acids encoding the same are suitable for treating lymphoproliferative disorders and solid tumours that express NGcGM3.

ENRICHED T-CELL POPULATIONS

Resumen de: AU2024350024A1

Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.

CBL-B INHIBITORS AND METHODS OF USES THEREOF

Resumen de: AU2024353668A1

Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.

MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA

Resumen de: WO2024254455A1

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

BCMA-targeted CAR-T-cell therapy for multiple myeloma

Resumen de: GB2644560A

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

CLL1-CAR-T CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4726031A1

This disclosure discloses a CLL1-CAR-T cell, as well as their preparation methods and applications. Specifically, it reveals CLL1-CAR-T cell that contain a chimeric antigen receptor, which comprises a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID No.1. The CLL1-VHH-1 CAR-T cells of this disclosure can effectively secrete the T-cell-specific effector molecule IFN-γ, specifically and efficiently kill CLL1⁺ target cells, and exhibit favorable in vivo anti-tumor activity. They not only significantly inhibit the proliferation of tumor cells in mice but also markedly prolong the survival time of mice. The CLL1-VHH-1 CAR-T cells of this disclosure demonstrate excellent anti-tumor capabilities and can be used for immunotherapy of diseases related to the CLL1 target, such as acute myeloid leukemia, presenting broad prospects for clinical applications.

DARATUMUMAB.BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR TREATING MULTIPLE MYELOMA

Resumen de: AU2025316407A1

The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.

CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND A GLUTAMINE TRANSPORTER, USES AND METHODS THEREOF

Resumen de: WO2026074086A1

The present invention relates to cells expressing chimeric antigen receptors against BCMA and a glutamine transporter, and uses thereof in the treatment of cancer or autoimmune diseases. The invention also relates to a method for the prognosis of multiple myeloma in a subject.

COMPOUNDS FOR TREATING MDS-ASSOCIATED ANEMIAS AND OTHER CONDITIONS

Resumen de: WO2026076363A1

Provided herein is the use of particular dose levels or amounts of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof, for treating anemia associated with low risk MDS, lower risk MDS and/or intermediate risk MDS (collectively, LRMDS) and other conditions.

IMMUNOTHERAPY

Resumen de: WO2026074291A1

The invention relates to immunotherapy, and to invariant natural killer T (iNKT) cells, and iNKT cell immunotherapy. The invention concerns CAR-iNKT cell immunotherapy, in particular, mono- and bi-specific CAR-iNKT cell immunotherapy, as well as pharmaceutical compositions comprising these iNKT cells, and to their use in therapy, as well as therapies and methods for treating, preventing, or ameliorating cancer or infection. The invention also concerns the treatment of various leukaemias, such as acute lymphoblastic leukaemia (ALL), including infant ALL.

USE OF INHIBITORS OF THE N-ACETYLASPARTATE SYNTHETASE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIAS

Resumen de: WO2026074142A1

OF THE INVENTION USE OF INHIBITORS OF THE N-ACETYLASPARTATE SYNTHETASE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIAS Acute Myeloid Leukemias (AML) are characterized by the proliferation of immature blood cells, leading to suppression of normal hematopoiesis. Despite existing treatments, resistance and relapse are common. A metabolomic analysis revealed increased N-Acetyl-Aspartate (NAA) levels in leukemic cells compared to normal HSCs, with high NAA levels linked to poor prognosis. The inventors studied the gene NAT8L, responsible for NAA synthesis, and found correlations with patient survival. Using CRISPR-cas9, the inventors targeted NAT8L in AML cell lines and observed that NAA depletion improved response to treatments and increased survival in vivo. Inhibiting NAA synthetase thus represents a therapeutic strategy to enhance chemotherapy efficacy and prevent relapse in AML patients.

METHOD FOR ASSESSING CLINICAL STAGE OR PREDICTING PROGNOSIS FOR CHEMOTHERAPY IN DOG WITH LYMPHOMA

Resumen de: WO2026075450A1

The present invention relates to a method for assessing disease severity or a clinical stage of, or predicting prognosis for chemotherapy in, dogs suffering from lymphoma. According to the present invention, in dogs suffering from lymphoma, it has been confirmed that CD34-positive expression is associated with a higher risk of cranial mediastinal lymph node metastasis and fever compared to CD34-negative expression; and since the CD34-positive expression is classifiable as a clinical disease within the WHO clinical substages, CD34 positivity can serve as an indicator of poor prognosis. In addition, it has been confirmed that MHC class II (MHCII)-positive expression is associated with a higher risk of fever and adverse effects from chemotherapy compared to MHCII-negative expression, and thus can serve as an indicator of favorable prognosis. Accordingly, the present invention may contribute not only to preserving companion dog health and reducing medical expenses for pet owners, but also to improving the quality of veterinary consultations.

TREATMENT OF LYMPHOMAS USING AN EZH2 INHIBITOR

Resumen de: WO2026076264A1

Provided here are methods of treating lymphomas for example, peripheral T-cell lymphomas (PTCLs) (e.g., nodal Tfh cell lymphomas) and/or cutaneous T-cell lymphomas (CTCLs) in a subject, by administering to the subject Compound A, or a pharmaceutically acceptable salt thereof. In some cases, the lymphomas are BCL6 positive. In some cases, the lymphomas are relapsed or refractory. In some cases, the subjects are treatment-naïve (i.e., previously untreated).

Cancer antigen targets and uses thereof

Resumen de: AU2026202107A1

The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens. 5 ar a r

IMMUNOTOXIN-BASED TARGETED THERAPY FOR CANCER

Resumen de: US20260098097A1

0000 Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.

CD19/C22 CAR T-CELL TREATMENT OF HIGH RISK OR RELAPSED PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Resumen de: US20260097122A1

The present disclosure relates to CD19/22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

ENHANCEMENT OF CAR-T CELL EFFICACY BY INHIBITING NR2F6

Resumen de: AU2024339935A1

The invention relates to a modified immune cells for use in the treatment of a solid tumor in a subject, wherein the modified immune cell comprises one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of said solid tumor, in said immune cell, Nuclear Receptor Subfamily 2 Group F Member 6 (NR2F6) activity is inhibited (in comparison to a control immune cell), and binding of the immune cell to the antigen is associated with death of said cancerous cell expressing the antigen, and inducing a secondary immune reaction in the subject against cancerous cells of the solid tumor, wherein said secondary immune reaction is non-specific to the antigen targeted by the transgenic construct (epitope spreading). The invention relates further to a modified immune cell comprising one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of a solid tumor, wherein in said cell, NR2F6 activity and Casitas B-lineage lymphoma proto-oncogene-b (CBLB) activity is inhibited (compared to a control immune cell). The invention relates further to a pharmaceutical composition comprising the modified immune, suitable for the treatment of a solid tumor, comprising additionally a pharmaceutically acceptable carrier, and to an in vitro method for enhancing the cytolytic activity of a modified immune cell.

PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA

Resumen de: EP4722388A1

The invention relates to a method of predicting an outcome of a subject having AML, the method comprising determining or receiving the result of a determination of six or more gene expression levels selected from a gene signature, and, optionally, providing the prediction to a medical caregiver or the subject. The invention further describes an apparatus and a computer program product configured to prediction outcome of a subject having AML. In addition the invention described the use of a kit in prediction outcome of a subject having AML, and describes a therapy for use in the treatment of AML, the use comprising predicting an outcome of a subject having AML and providing a therapy adapted to the outcome.

METHODS FOR TREATING MULTIPLE MYELOMA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

CD19CAR T-CELL TREATMENT OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

Nº publicación: EP4719463A1 08/04/2026

Solicitante:

AUTOLUS LTD [GB]

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.